<div id="readability-page-1"><p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the fifteen analysts that are currently  covering the firm, Marketbeat.com reports. One investment analyst  has rated the stock with a sell rating, thirteen have given a buy rating and one  has given a strong buy rating to  the company. The average 12 month price target among analysts that have covered the stock in the last year is $12.2308.</p><div><p><span></span><span>Get <strong>Compass Therapeutics</strong> alerts:</span></p></div><ul><li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li></ul><p>A number of brokerages recently commented on CMPX. Lifesci Capital assumed coverage on Compass Therapeutics in a report on Monday, October 6th. They set an &#34;outperform&#34; rating and a $10.00 target price for the company. William Blair started coverage on Compass Therapeutics in a research report on Monday, January 5th. They set an &#34;outperform&#34; rating on the stock. Compass Point  set a $10.00 target price on Compass Therapeutics in a report on Monday, October 6th. Citizens Jmp began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a &#34;market outperform&#34; rating and a $10.00 price target on the stock. Finally, JMP Securities  set a $10.00 price objective on Compass Therapeutics in a research report on Wednesday, December 3rd.</p><p><b>Read Our Latest Research Report on Compass Therapeutics</b></p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds have recently made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new stake in  Compass Therapeutics during the fourth quarter worth approximately $32,000.  Tema Etfs LLC acquired a new stake in  Compass Therapeutics during the fourth quarter worth approximately $538,000.  Avanza Fonder AB purchased a new stake in shares of  Compass Therapeutics during the 4th quarter worth approximately $147,000.  CIBC Bancorp USA Inc. purchased a new stake in shares of  Compass Therapeutics during the 3rd quarter worth approximately $37,000.  Finally, Vivo Capital LLC boosted its holdings in shares of  Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Hedge funds and other institutional investors own  68.43% of the company's stock. </p><h2>Compass Therapeutics Price Performance</h2><p>Shares of CMPX stock opened at $6.19 on Tuesday. Compass Therapeutics has a 1-year low of $1.33 and a 1-year high of $6.40. The firm has a market cap of $1.10 billion, a PE ratio of -13.76 and a beta of 1.45. The company has a 50-day moving average of $5.34 and a two-hundred day moving average of $4.18. </p><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06.  Sell-side analysts anticipate that  Compass Therapeutics will post -0.36 EPS for the current fiscal year. </p><h2>About Compass Therapeutics</h2> (Get Free Report)<p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.  </p><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Compass Therapeutics</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2><p>Before you consider Compass Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CMPX

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus rating of "Moderate Buy" from fifteen analysts. Among them, one analyst rated it as a sell, thirteen as buy, and one as strong buy. The average 12-month price target is $12.23. Recent coverage includes an "outperform" rating with a $10 target price from Lifesci Capital. Hedge funds own 68.43% of the stock, which opened at $6.19, with a 1-year low of $1.33 and a high of $6.40. The company reported an EPS of ($0.08) for the last quarter, exceeding estimates.</p>

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Analysts